Invicro UK (formerly Imanova) is undertaking studies with beta amyloid radioligands such as Amivid, Neuroseq and Vizamyl, designed to stratify subjects into Phase II studies, looking at the treatment of Alzheimer’s disease.
Invicro UK has also implemented Tau PET-radioligand 18F-T807. Ongoing studies are evaluating the utility of 18F-T807 to quantify Tau protein density in conditions such as Alzheimer’s disease, Cortico-basal degeneration, frontico tempral dementia and traumatic brain injury.